WHO issues new hepatitis C guidelines, EASL guidelines update forthcoming in September
Portugal's roll-out of HCV therapy with DAAs achieves impressive results
DAAs achieve excellent outcomes in real-world settings
Sofosbuvir/velpatasvir + GS-9857 works well for treatment-experienced hepatitis C patients
Ravidasvir plus sofosbuvir demonstrates high cure rate for people with hepatitis C genotype 4
New Merck combination pill Zepatier approved for hepatitis C treatment in the United States
A quarter of people with HCV initially refused access to sofosbuvir/lepidasvir, says US study, but most successfully appeal
Grazoprevir/elbasvir cures more than 90% of people with HIV/HCV co-infection
